Aptevo Therapeutics (APVO) Reports FY22, Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
March 30, 2023 7:47 AM EDTCompany Achieves Multiple Clinical and Scientific Milestones in 2022, Poised for APVO436 Phase 2 in AML 2H23, ALG.APV-527 dosing initiated 1Q23 for Solid Tumors
SEATTLE, WA / ACCESSWIRE / March 30, 2023 / Aptevo Therapeutics Inc. (NASDAQ: APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR" and ADAPTIR-FLEX" platform technologies, today reported financial results for the year ended December 31, 2022 and business highlights.
2022 Highlights
APVO436 (Acute Myeloid Leukemia)
In December 2022 we announced that APVO436, in combination with venetoclax and azacitidine, demonstrated... More
